Live Breaking News & Updates on Maria hafez

Stay informed with the latest breaking news from Maria hafez on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Maria hafez and stay connected to the pulse of your community

Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Maria-hafez , Sidney-kimmel-medical-college , Thomas-jefferson-university , Clinical-breast-cancer-research , D , Federica-trial , Patients-with-her2-positive-early-breast-cancer ,

Dr Hafez on the Influence of Biomarker Expression on Adjuvant T-DM1 Use in HER2+ Breast Cancer

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Maria-hafez , Breast-cancer-clinical-research , Sidney-kimmel-medical-college , Thomas-jefferson-university , Sidney-kimmel-cancer-center , Prediction-analysis , Absolute-intrinsic-molecular-subtyping , D , Onclive , Early-stage-her2-positive-breast-cancer- ,

Dr Hafez on Key Considerations For Treatment Selection in Early-Stage HER2+ Breast Cancer

Maria Hafez, MD, discusses how hormone receptor status, risk stratification, and other disease factors influence the treatment decision-making process in patients with early-stage HER2-positive breast cancer.

Maria-hafez , Key-considerations-for-treatment-selection , Partnership-with , D , Onclive , Early-stage-her2-positive-breast-cancer- ,

Exploratory Analyses of KATHERINE Trial Inform Adjuvant T-DM1 Use in HER2+ Breast Cancer

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.

Philadelphia , Pennsylvania , United-states , Maria-hafez , Sidney-kimmel-medical-college , Science-summit , Breast-cancer-clinical-research , Sidney-kimmel-cancer-center , Thomas-jefferson-university , Prediction-analysis , Absolute-intrinsic-molecular , Katherine-trial

Biomarker Data and Patient Preference Inform Perioperative Therapy Selection in Early HER2+ Breast Cancer

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.

Philadelphia , Pennsylvania , United-states , Maria-hafez , Sidney-kimmel-medical-college , Science-summit , Breast-cancer-clinical-research , Sidney-kimmel-cancer-center , Thomas-jefferson-university , Biomarker-data , Perioperative-therapy , Her2-breast-cancer